Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 12,206 shares of the business’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $13.52, for a total value of $165,025.12. Following the transaction, the chief executive officer now owns 340,207 shares of the company’s stock, valued at approximately $4,599,598.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Shares of Amicus Therapeutics, Inc. (NASDAQ FOLD) traded up $0.02 during mid-day trading on Wednesday, hitting $13.00. The company’s stock had a trading volume of 1,583,811 shares, compared to its average volume of 3,147,920. Amicus Therapeutics, Inc. has a twelve month low of $4.41 and a twelve month high of $16.60. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The firm had revenue of $10.90 million during the quarter, compared to analysts’ expectations of $9.02 million. During the same quarter in the prior year, the company posted ($0.33) earnings per share. Amicus Therapeutics’s quarterly revenue was up 419.0% compared to the same quarter last year. equities analysts forecast that Amicus Therapeutics, Inc. will post -1.56 EPS for the current year.
Several hedge funds have recently modified their holdings of the business. Sage Capital Advisors llc purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $154,000. GSA Capital Partners LLP bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth $309,000. Iguana Healthcare Management LLC bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth $905,000. Sterling Capital Management LLC bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth $218,000. Finally, Neuberger Berman Group LLC bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth $196,000.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.